Market Insights
The thyroid gland disorders treatment market is propelling due to factors such as the rise in the patient base suffering from thyroid disorders, the rising geriatric population, and the consistent introduction of innovative and novel therapeutics by market players, leading to the growth of the market.
Asia Pacific is expected to be the fastest-growing market in the thyroid gland disorder treatment market due to a large patient base leading to large consumption of generic drugs for the treatment of thyroid diseases, especially in countries such as China, India, and Japan. Moreover, the growing research and development in the drug discovery of thyroid gland disorders would further drive the market during the forecast period.
The “Thyroid Gland Disorders Treatment Market: Growth, Share, Opportunities, and Competitive Analysis, 2016–2023” offers strategic insights into the overall thyroid gland disorders treatment market, along with the market size and estimates for the duration of 2016–2023. The said research study covers an in-depth analysis of multiple market segments based on the type of treatment and different geographical regions.
The treatment type segments studied for analyzing the overall thyroid gland disorders treatment market are hypothyroidism and hyperthyroidism treatment. Hypothyroidism treatment includes drugs such as levothyroxine and liothyronine, while hyperthyroidism treatment includes drugs such as imidazole and propanil. To help strategic decision-makers, the report also includes competitive profiling of the leading players in the thyroid gland disorders treatment market, attractive investment propositions, and market positioning of key manufacturers. Other in-depth analysis provided in the report includes:
Geographically, the thyroid gland disorders treatment market is studied for the following regional markets:
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2013–2023. Market growth rates for the forecast period 2016–2023 are also included in this report, considering 2015 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global thyroid gland disorders treatment market. Tools such as the market positioning of key players and an attractive investment proposition provide the readers with insights into the competitive scenario of the global thyroid gland disorders treatment market. This report concludes with a company profiles section that highlights major information about the key players engaged in the thyroid gland disorders market. In-depth competitive environment analysis and historical years (2013 and 2014) of market size data are also provided in the report.
Thus, the research study provides a holistic view of the global thyroid gland disorders treatment market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the factors mentioned above.
Based on the type of treatment, the global thyroid gland disorders treatment market is segmented as follows:
- Hypothyroidism
- Levothyroxine
- Liothyronine
- Hyperthyroidism
- Imidazole
- Tropical
Thyroid gland disorder is characterized by underactive or overactive production of thyroid hormones (T3 and T4), termed hypothyroidism or hyperthyroidism, respectively. Thyroid disorders can range from a small, harmless goiter (an enlarged gland) that needs no treatment to life-threatening cancer. The most common thyroid problems involve abnormal production of thyroid hormones. Too much thyroid hormone results in a condition known as hyperthyroidism. Insufficient hormone production leads to hypothyroidism. Thyroid gland disorders affect around 5% to 10% of the human population globally. Women are more susceptible to thyroid problems.
More than 12 percent of the U.S. population will develop a thyroid condition during their lifetime. An estimated 20 million Americans have some form of thyroid disease. The thyroid gland disorders treatment market is segmented into hypothyroidism and hyperthyroidism treatment. Hypothyroidism treatment includes drugs such as levothyroxine and liothyronine, while hyperthyroidism treatment includes drugs such as imidazole and propanil. The thyroid gland disorders treatment market is propelling due to factors such as the rise in the patient base suffering from thyroid disorders, the rising geriatric population, and the consistent introduction of innovative and novel therapeutics by market players, leading to the growth of the market.
For this study, the global thyroid gland disorder treatment market is categorized as follows:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
The geographical segmentation of the global market for thyroid gland disorders treatment comprises North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. In the base year of 2015, North America accounted for the largest market in the thyroid gland disorders treatment market due to the rising number of patients suffering from thyroid diseases in the U.S. According to the American Thyroid Association (ASA), more than 12% of the U.S. population will develop a thyroid condition during their lifetime, and an estimated 20 million Americans have some form of thyroid disease.
Moreover, mandatory screening of newborns for congenital hypothyroidism and cost-effective methods to detect thyroid cancer by screening would further expand the thyroid gland disorders treatment market. Rising patient populations in Europe are expected to drive the European thyroid gland disorders treatment market during the forecast period. Asia Pacific is expected to be the fastest-growing market in the thyroid gland disorder treatment market due to a large patient base leading to large consumption of generic drugs for the treatment of thyroid diseases, especially in countries such as China, India, and Japan. Moreover, the growing research and development in the drug discovery of thyroid gland disorders would further drive the market during the forecast period.
